Regorafenib

CAS 755037-03-7 7 current recordsSmall Molecule

Who holds supplier records for Regorafenib? 7 organisations hold a current record for Regorafenib: an active US FDA Type II Drug Master File or a CEP. 1 of them holds a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (5) and India (2).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Regorafenib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/regorafenib

Reading the evidence

  • 7 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in China

    5 of the 7 current records with a recorded country list China. Organisation country is not necessarily the manufacturing site.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Regorafenib expires 9 Jul 2032. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (7)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Regorafenib. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Regorafenib sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (1)

Certificates of Suitability on the EDQM register for Regorafenib, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
MSN LABORATORIES PRIVATE LIMITED Kardanur VillageIN
CEP 2022-456 - Rev 00
Regorafenib monohydrate, Crystalline form
Feb 2025Inspected Aug 2026
Slovakia

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Regorafenib). The latest listed patent expires 9 Jul 2032. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Regorafenib is a multi-kinase inhibitor that targets various pathological kinases to impede cancer cell proliferation and angiogenesis. It is primarily used for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumors.

Chemical identity

IUPAC name
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;hydrate
Canonical SMILES
CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.O
InChIKey
ZOPOQLDXFHBOIH-UHFFFAOYSA-N
Synonyms
Stivarga API, bay-73-4506 monohydrate, bay-734506 monohydrate, regorafenib hydrate, regorafenib monohydrate, stivarga

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor
Mechanism of action
Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2C9 Inhibitors; Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A9 Inhibitors

Therapeutic areas

OncologyGastroenterologyHepatology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Regorafenib?

7 organisations hold an active US FDA Type II Drug Master File or a CEP for Regorafenib: MSN Laboratories Private Limited (India), Sichuan Kelun Pharmaceutical Co., Ltd. (China), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (China), Hetero Labs Limited (India), Shandong Anhong Pharmaceutical Co., Ltd. (China), YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTD (China) and Zhejiang Huayi Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Regorafenib Drug Master Files are active?

MSN Laboratories Private Limited (DMF 29870, 36838), Sichuan Kelun Pharmaceutical Co., Ltd. (DMF 44790, 42842), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (DMF 38197), Hetero Labs Limited (DMF 30490), Shandong Anhong Pharmaceutical Co., Ltd. (DMF 41596), YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTD (DMF 41290) and Zhejiang Huayi Pharmaceutical Co., Ltd. (DMF 39898). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Regorafenib have a European Certificate of Suitability?

Yes. 1 organisation holds a valid CEP for Regorafenib on the EDQM register, including MSN LABORATORIES PRIVATE LIMITED Kardanur Village (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Regorafenib?

Yes. The latest patent listed for an approved US product containing Regorafenib expires 9 Jul 2032, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Regorafenib supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Regorafenib?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.